Last update Oct. 9, 2016
Non-ergotamine and D2 /D3 Dopamine agonist drug.
Indicated for Parkinson's disease and Restless Legs Syndrome (Evening dose).
At latest update no published data on excretion into breast milk were found.
Pharmacokinetic data do not allow easily predict the possibility of excretion into breastmilk, since a low protein-binding capacity would not prevent it, however, a large distribution volume would make it unlikely.
Its low oral bioavailability which decreases even more when taken with meals, suggests that plasma concentration would reach a very low level in the infant, except during the neonatal period and in case of prematurity in which intestinal absorption may be increased.
Side effects are neither frequent nor severe.
Prolactin levels may be lowered with decreased production of breastmilk during the first weeks after birth.
Gut absorption may be increased with higher plasma levels if taken together with Ciprofloxacin (Kaye 2000).
Whenever it is used while breastfeeding, it would be wise avoiding it during the first 15 to 20 days and assess milk production and onset of nausea, drowsiness or irritability in infants.
By waiting six hours after medication, excretion into breastmilk would possibly be lowered.
We do not have alternatives for Ropinirole Hydrochloride.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2012 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM